- This event has passed.
A Virtual Fireside Chat with Drs. Don and Lisa Drakeman
June 22 @ 3:00 pm - 4:00 pm
During this virtual fireside chat, hear from the authors of “From Breakthrough to Blockbuster: The Business of Biotechnology” on how new medicines come into being, why the process is so breathtakingly expensive and how small entrepreneurial ventures can compete in one of the world’s most expensive and heavily regulated industries.
Industry veterans Drs. Don and Lisa Drakeman will share an inside look at how inexperienced, underfunded and unprofitable small companies have created more life-changing new medicines than the largest global pharmaceutical firms.
|“We are thrilled to welcome back two dear friends and important early BioNJ leaders, Drs. Don and Lisa Drakeman, for an insightful discussion of their new book. Don was BioNJ’s founding Vice Chair and our second Chair and Lisa is a former Board Member. They were both absolutely essential to the successful foundation of BioNJ and immense contributors to the NJ ecosystem.” ~ Debbie Hart, President & CEO, BioNJ|
|Don Drakeman, Ph.D.
Dr. Drakeman was the founding CEO of the U.S. biotech company that pioneered the development of the checkpoint inhibitor cancer treatments recognized in the Nobel Prize for Medicine 2018. These products, YERVOY and OPDIVO, are being used to treat many different forms of cancer. He is a Fellow in Operations and Technology Management at the Cambridge Judge Business School, Distinguished Research Professor in the Center for Citizenship and Constitutional Government at the University of Notre Dame, and a Venture Partner at Advent Life Sciences. His publications have been cited in numerous patents and by the Supreme Court of the United States. He is a Fellow of the Royal Society of Biology. A graduate of Columbia Law School, he received a Ph.D. from Princeton University.
|Lisa Drakemam, Ph.D.
Dr. Drakeman was the founding CEO of one of Europe’s most successful biotechnology companies. Under her leadership, the company set numerous financing records, including a record setting IPO, and inaugurated research programs leading to the new FDA-approved medicines DARZALEX (multiple myeloma) and KESIMPTA (multiple sclerosis). She is a member of the board of the Medical University of South Carolina Foundation for Research Development. She has received numerous industry honors, including the Sol J. Barer Award for Vision, Innovation, and Leadership. She has been a faculty member at Princeton University and regularly lectures on entrepreneurship at universities in the U.S. and Europe. She received a Ph.D. from Princeton University.
Entrepreneurs, scientists, investors, policy makers and students alike will enjoy and learn from this engaging discussion. BioNJ Members are invited to attend at no cost. Registration for Future Members is $125. Click here to register.